We give you many useful information about health

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

We give you many useful information about health

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

We give you many useful information about health

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

We give you many useful information about health

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

We give you many useful information about health

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

Sabtu, 08 Oktober 2011

Why Are So Many Seniors Getting End-of-Life Surgery?

AppId is over the quota
AppId is over the quota

One in three people on Medicare have surgery in the final year of their lives, and many have surgery in their last month, according to a new study published in The Lancet.

Of the 1.8 million Medicare patients over age 65 who died in 2008, researchers found that a third had undergone surgery in the year before death and that 18% of those surgeries had occurred in the month before death. Nearly 1 in 10 had surgery in their final week. The numbers were surprisingly high, researchers said.

To some extent, the finding makes sense: sick people have surgery and sick people also die. But while the researchers did not examine whether individual surgeries were necessary or whether they improved patients' quality of life — many surely did — the data suggested they did not improve outcomes overall. Areas of the country that had high rates of surgery also had high rates of death.

MORE: Anesthesia May Put Kids at Risk for Learning Disabilities

Geography had a lot to do with a Medicare patient's likelihood of having surgery in the last year of life. Muncie, Ind., had the highest rate, at 34%, while Honolulu had the lowest, at 12%. Why that's so isn't clear, but the authors suggested several possible contributing factors, including population health, patterns of medical practice, culture and availability of end-of-life services such as hospice care.

Rates of surgery also differed by age. About 38% of 65-year-old Medicare patients had surgery in the year they died, compared with 35% of 80-year-olds — not a very vast difference. But rates of surgery dropped off more sharply in patients older than 80, with fewer than 24% of patients between 80 and 90 having surgery, suggesting that surgeons had greater concerns about the risk of complications in this age group.

Given the patterns in surgery rates across the country, the authors suggest that medical need is not the only factor driving doctors' desire to operate. Many surgeries may be done to avoid difficult discussions about patients' prognosis, or to fix problems that wouldn't necessarily prolong life or improve its quality, the authors said. Doctors are also failing to figure out exactly how dying patients wish to spend their final days.

MORE: Breaking a Hip More Than Doubles Women's Risk of Death

"In a lot of places, we're doing a lot of these surgeries I think unnecessarily," lead author Ashish Jha, a professor of health policy and management at the Harvard School of Public Health, told Bloomberg. "We're not having the kinds of conversations with patients that we need to have, about what they want out of their last few days and how we help them achieve those goals."

Reported Bloomberg:

Doctors and hospitals may have a financial incentive to operate on dying seniors "regardless of the patient's preferences or goals," because Medicare is guaranteed to pay for the procedures, said Amy Kelley, an assistant professor of Geriatrics and Palliative Medicine at Mount Sinai School of Medicine in New York.

In an accompanying comment in The Lancet, Kelley wrote that doctors', insurance companies' and hospitals' incentives must be aligned with the wishes of the patient. She also suggested that another to way to increase the likelihood that patients get the care they want is to ensure that all medical and nursing school students receive basic education in end-of-life care

The study is not without its limitations, however. For example, researchers looked only at surgery patients who died; it's not known how many patients who had the same procedure survived.

MORE: Deep Fear of Childbirth Drives Some C-Sections

Meredith Melnick is a reporter at TIME. Find her on Twitter at @MeredithCM. You can also continue the discussion on TIME's Facebook page and on Twitter at @TIME.



News



Debt Financing

Antioxidants tied to mixed effects in breast cancer

AppId is over the quota
AppId is over the quota
By Amy Norton

NEW YORK | Fri Oct 7, 2011 4:20pm EDT

NEW YORK (Reuters Health) - Breast cancer patients who take antioxidants may have an increased or decreased risk of death or recurrent cancer, depending on which vitamin they use, a new study suggests.

Researchers found that among nearly 2,300 women with early-stage breast cancer, those who regularly used either vitamins C or E had a lower risk of cancer recurrence over five years than those who didn't use the vitamins.

On the other hand, women who regularly took a mix of carotenoids had a higher risk of dying from breast cancer, or any other cause, than women who did not take them.

Carotenoids include nutrients like vitamin A, beta-carotene and lutein.

The findings, reported in the journal Cancer, do not prove that any of the antioxidants are the reason for the effects seen.

But they do add to concerns about the risks of high doses of carotenoids, according to lead researcher Heather Greenlee, an assistant professor of epidemiology at Columbia University in New York.

"In my opinion," she told Reuters Health in an email, "our paper adds to the growing body of literature suggesting that dietary supplements containing high doses carotenoids may be harmful, and people should think twice before taking them."

Studies have found, for example, that giving beta-carotene supplements to smokers may actually raise their risk of lung cancer.

As for other antioxidants, Greenlee noted that the American Cancer Society and the American Institute for Cancer Research say that there's not enough evidence to recommend any dietary supplement for preventing cancer, or a cancer recurrence.

There is also concern about patients taking high doses of any antioxidant while on chemotherapy or radiation.

Antioxidants protect body cells from so-called oxidative damage. Cancer drugs and radiation work in part by creating oxidative damage. So in theory, high-dose antioxidants could diminish the treatments' effectiveness.

Still, studies show that women with breast cancer commonly use antioxidant supplements of some kind.

The current findings are based on questionnaires and case data from 2,264 U.S. women diagnosed with early-stage breast cancer.

Overall, 81 percent said they'd used at least one supplement containing antioxidants -- either within multivitamins or in the form of single-vitamin supplements -- in the two years after being diagnosed.

Over the next five years, the study found, women who'd reported using single supplements of either vitamin C or vitamin E six to seven days a week had a lower risk of cancer recurrence.

Of 540 women who took vitamin C, 15 percent had a breast cancer recurrence. That compared with 19 percent of the 1,072 women who did not use vitamin C supplements.

The differences were about the same when the researchers looked at vitamin E.

On the other hand, women who used any combination of carotenoids had a higher risk of dying from breast cancer, or from any cause. Of 89 women who used carotenoids six to seven days per week, 18 percent died of breast cancer; that compared with just under seven percent of women who did not use carotenoid combinations.

According to Greenlee, much of the benefit associated with vitamins C and E could potentially be explained by a "healthy user bias" -- that is, women who use dietary supplements tend to have healthier habits in general.

And that, she and her colleagues write, makes the increased risk of death linked to carotenoid use "even more striking."

The reasons for the different breast cancer outcomes linked to different antioxidants are not known, and the findings need to be confirmed in further studies, Greenlee said.

The most important point this study raises, she added, is that "antioxidant dietary supplements should not be assumed to all act in a similar fashion, as is a common perception in the general public."

"They are made up of different molecules," Greenlee said, "and likely have different effects."

On the other hand, the researchers found no evidence that breast cancer recurrence or deaths were linked to antioxidants taken within multivitamins -- which generally have more moderate doses of individual nutrients.

SOURCE: bit.ly/rkf6uw Cancer, online September 27, 2011.



New Automobile



Health Management

Zytiga creeps up on Provenge prostate-cancer drug

AppId is over the quota
AppId is over the quota
By Ransdell Pierson

NEW YORK | Fri Oct 7, 2011 3:19pm EDT

NEW YORK (Reuters) - Interest in Dendreon Corp's Provenge vaccine to treat prostate cancer seems to be waning following recent approval of Johnson & Johnson's more-convenient and faster-acting Zytiga treatment, according to some doctors and industry analysts.

"The bloom is off the rose for Provenge because patients are looking for something that can treat them more quickly," and with greater convenience, said Charles Duncan, a biotechnology analyst for JMP Securities.

Although Provenge extended patient lives by an average of about four months in clinical trials, it does not significantly delay progression of symptoms -- including the bone pain which is a hallmark of advanced prostate cancer.

Even so, hopes for Provenge were sky high when U.S. regulators approved it in April 2010 for patients with prostate cancer who had failed to benefit from standard medicines that work by blocking the body's production of testosterone. Some analysts had expected the vaccine, which spurs the immune system to attack prostate cancer cells, to eventually capture annual sales of more than $4 billion.

But Duncan, whose company helped sponsor the "Cancer Immunology: A Long-Awaited Reality" conference in New York on Thursday, said Provenge is likely to generate peak annual sales of no more than $500 million because of shortcomings that have become evident to patients and doctors.

They include the time and inconvenience of extracting white blood cells from patients and sending them off to Dendreon plants, where they are combined with vaccine components. Patients then receive the final product through infusions.

Dr. Susan Slovin, an oncologist with Memorial Sloan-Kettering Cancer Center, said many patients and doctors are gravitating instead toward J&J's Zytiga -- a pill approved in recent months for advanced prostate cancer patients that have failed to benefit from chemotherapy.

The drug, known by its chemical name abiraterone, also prolonged life by about four months in clinical trials. But patients experience symptom relief far sooner with it than with Provenge, said Slovin, who was interviewed at the conference sponsored by strategy consulting firm MD Becker Partners LLC.

J&J'S PILL COMING ON STRONG

"Abiraterone is taking the market by storm; there is a much faster effect with it" than Provenge, Slovin said. "Patients feel they're getting something beneficial. Pain is markedly improved, along with the ability to eat, drink, go out and do what they normally would do."

"The patient says, 'Look, I really don't see the need to sit here and send my (blood) to wherever. I really don't want to wait. I want to take a pill and go to Florida.' "

Moreover, while Zytiga is expensive -- at about $5,000 a month, usually for eight cycles -- it is far less costly than Provenge.

Dendreon stunned investors in August by withdrawing its own sales forecast for Provenge because it was taking longer than expected for doctors to become comfortable with reimbursement issues for the product, which costs $93,000 for a course of treatment.

"I don't think Provenge will fall out of the arena; I do think it will still be used, but not with the same alacrity as when it first hit our formulary," said Slovin, whose hospital is one of the world's most prestigious cancer centers.

Dr. James Gulley, a director of clinical trials for the National Cancer Institute, said there is a "clear utility" for Provenge.

"Patients love the idea that your immune system is helping you fight cancer," he said. But Gulley said its manufacturing process poses challenges that have no doubt hampered demand for the product. "The vaccine has to be made for each individual patient."

Gulley is leading clinical trials of an experimental vaccine to treat prostate cancer that could be taken out of the freezer and injected into patients -- eliminating the hassles seen with Provenge.

The National Cancer Institute developed the vaccine, called ProstVac, and licensed it to Danish biotechnology company Bavarian Nordic. NCI would be entitled to royalties on sales of the vaccine, which is slated to move into late-stage trials in coming weeks.

Gulley said ProstVac prolonged patient lives by eight months in mid-stage trials -- roughly twice the benefit seen in separate trials of Provenge and Zytiga. But he cautioned that ProstVac's true potential will not be known until its far-larger planned Phase III trials are completed.

He said the vaccine, which coaxes immune system T-cells to attack a protein called Prostate-Specific Antigen (PSA) -- could prove to be a bigger drug than Provenge.

"Here's why: because it is off the shelf. There are no logistical constraints."

Currently, the world's top selling prostate cancer drugs are Taxotere (docetaxel), a chemotherapy sold by Sanofi, and drugs that reduce testosterone, the male hormone that fuels the growth of prostate cancer. They include AstraZeneca Plc's Zoladex and Casodex, and widely-used Lupron.

Prostate cancer kills about 250,000 men a year globally and is the second most common cause of cancer death in men in the United States, after lung cancer.

(Reporting by Ransdell Pierson, editing by Bernard Orr)



New Automobile



Health Management

Diet tricks the pros tell their friends

AppId is over the quota
AppId is over the quota
Variety, color and presentation go a long way toward fooling your stomach. Variety, color and presentation go a long way toward fooling your stomach. Taste buds learn to love the food they're with -- so make a commitment to wholesome foodsEat small amounts of dark chocolate every day to avoid bingeing on sweetsHide your craving food in a hard-to-get-to place so you have to work to find it

(Health.com) -- Wish you had your own get-slim dream team? Well, you're in luck: We tapped celebrated weight-loss pros and asked them to share the one strategy they feel makes the biggest difference.

Weave these seven wonders into your daily routine, and you'll be wowed by how the little changes really do add up.

1. Trick your taste buds

"Taste buds are malleable little fellas. When they can't be with the foods they love, they learn to love the foods they're with. Make a short-term commitment to choosing more wholesome closer-to-nature foods with less added salt, sugar, saturated fat, and trans fat. Within weeks, you'll start to prefer these now-familiar foods."

-- David Katz, M.D., director of the Yale University Prevention Research Center

Health.com: 25 foods with tons of hidden salt

2. Indulge every day

"Eat a small amount of dark chocolate -- I'm talking a 100-calorie piece that's made of at least 70 percent cacao -- every day. I consider it 'the daily dark chocolate escape.' Doing this curbs your cravings for both sweet and salty foods. You're much more likely to be satisfied and not reach for those cookies or chips. My clients say this allows them to pass up samples at the market without feeling deprived."

-- Cynthia Sass, R.D., author of "Cinch! Conquer Cravings, Drop Pounds, and Lose Inches" and co-author of "The Ultimate Diet Log"

3 . Bury your cravings

"If you're a soda-lover -- or have another favorite calorie-laden indulgence like potato chips -- hide your stash in a really inconvenient place, like your basement. I do this myself. You'll be less likely to go and grab it. And if you do make the trek, you'll have to burn extra calories to get the treat."

-- Brian Wansink, Ph.D., director of the Cornell Food and Brand Lab and author of "Mindless Eating: Why We Eat More Than We Think"

Health.com: How the pros curb food cravings

4. Go for omega-3s

"Get into the habit of popping DHA-based omega-3s -- take two 200-milligram capsules about 30 minutes before both lunch and dinner. Or have 4 ounces of non-fried salmon or trout three times per week, along with six walnuts before each meal. This will decrease your desire for food later on, since this type of omega helps release the hormone cholecystokinin, which reduces appetite. Less food equals a smaller waist!"

-- Michael Roizen, M.D., chief wellness officer at the Cleveland Clinic and co-author of "You: On a Diet" and "You: Stress Less"

5. Order with ice

"At a restaurant, make sure your water glass is always topped off and that it's ice cold. Drinking water throughout your meal makes you feel fuller faster, and the coldness causes you to burn more calories to bring the water's temperature up."

-- David Kirsch, New York City-based celebrity trainer (clients include Heidi Klum and Liv Tyler) and author of "The Ultimate New York Diet"

Health.com: Tricks to help you feel full

6. Plate like a French woman

"French women eat smaller portions of more things, and American women eat larger portions of fewer things. So plate your meal like a French woman! For breakfast, eat a slice of toast, a sliver of butter, a bit of jam, and a fruit—like half a banana—plus coffee or tea. Variety, color, and presentation go a long way toward fooling the stomach into thinking you're eating more than you actually are."

-- Mireille Guiliano, author of "French Women Don't Get Fat"

7. Up the burn

"Eating protein within 45 minutes after a moderate to intense workout (of at least 45 minutes to an hour) helps your muscles rebuild and repair -- and also helps increase the number of calories you burn. So for maximum fat-melting throughout the day, bring a small protein-rich 100- to 200-calorie snack with you to the gym, or keep a stash of yogurt or string cheese at work."

-- Teddy Bass, L.A.--based celebrity trainer who has worked with Cameron Diaz and Christina Applegate

Copyright Health Magazine 2010



Education Information



Technology

Legionnaires' link to Corfu break

AppId is over the quota
AppId is over the quota
7 October 2011 Last updated at 15:27 GMT By James Gallagher Health reporter, BBC News Legionella bacteria Legionnaires' disease is caused by bacteria and is a form of pneumonia There have been nine cases of Legionnaires' disease in the UK, all linked to travel to Corfu since August, according to the Health Protection Agency.

However, the HPA cannot rule out a UK source of the infections and is still investigating.

It is advising people to be aware of the symptoms of Legionnaires' disease if they are going to the Greek island.

The illness can lead to severe pneumonia and is sometimes fatal.

Symptoms can take up to two weeks to develop after infection and generally start as a "flu-like" illness. It can be treated with antibiotics.

The bacteria which cause the disease cannot be spread from person to person. They can live in water so cooling systems, showers and taps are common sources of infection.

Prof Nick Phin, from the Legionnaires' disease department at the HPA, said: "We are concerned that UK residents travelling to Corfu should be aware of this potential risk, however we are not suggesting that people change their holiday plans.

"We are continuing our investigations so we that can provide the best advice for travellers and minimise the risk of further cases.

"We will also assist the Greek Public Health authorities in their investigations into a possible source or sources within Corfu."

GPs in the UK are also being told to keep an eye out for patients with the symptoms of Legionnaires' disease.



Debt Financing



Career Advisor

CDC: Self-reported drunken driving is down

AppId is over the quota
AppId is over the quota
ATLANTA (AP) — Drunken driving incidents have fallen 30 percent in the last five years, and last year were at their lowest mark in nearly two decades, according to a new federal report.

The decline may be due to the down economy: Other research suggests people are still drinking as heavily as in years past, so some may just be finding cheaper ways of imbibing than by going to bars, night clubs and restaurants.

"One possibility is that people are drinking at home more and driving less after drinking," said Dr. Thomas Frieden, director of the Centers for Disease Control and Prevention.

The CDC statistics — released Tuesday — are based on a 2010 national telephone survey of about 210,000 U.S. adults. The respondents were kept anonymous.

Nearly 1 in 50 said they'd driven drunk at least once in the previous month. That equates to about 4 million Americans driving drunk last year.

About 60 percent said they drove drunk just once, but some said they did it daily.

That led to a CDC estimate of more than 112 million episodes of drunken driving in 2010. That's more than 300,000 incidents a day.

CDC officials lamented that finding; still, it was the lowest estimate since the survey question was first asked in 1993, and down significantly from the 161 million incidents in the peak year of 2006.

Young men ages 21 to 34 were the biggest problem, accounting for just 11 percent of the U.S. population but 32 percent of the drunken driving incidents.

The overwhelming majority of drunken driving incidents involve people who had at least four or five drinks in a short period of time. But binge drinking has not been on the decline, other health research suggests.

The National Highway Traffic Safety Administration has also noted signs of an apparent recent decline in drunken driving. According to that agency's latest data, the number of people killed in U.S. crashes involving alcohol-impaired drivers dropped from 11,711 in 2008 to 10,839 in 2009.

"While the nation has made great strides in reducing drunk driving over the years, it continues to be one of the leading causes of death and injury on America's roads — claiming a life every 48 minutes," added David Strickland, the agency's administrator, in a prepared statement.

___

Online:

CDC report: http://www.cdc.gov/vitalsigns

Associated Press

Technology



News

Pancreatic cancer declining, but among most deadly

AppId is over the quota
AppId is over the quota
FILE - In this Jan. 6, 2004 file photo, Apple CEO Steve Jobs displays the iPod mini at the Macworld Conference and Expo in San Francisco. Jobs, the Apple founder and former CEO who invented and masterfully marketed ever-sleeker gadgets that transformed everyday technology, from the personal computer to the iPod and iPhone, died Wednesday. He was 56. (AP Photo/Marcio Jose Sanchez, File) FILE - In this Jan. 6, 2004 file photo, Apple CEO Steve Jobs displays the iPod mini at the Macworld Conference and Expo in San Francisco. Jobs, the Apple founder and former CEO who invented and masterfully marketed ever-sleeker gadgets that transformed everyday technology, from the personal computer to the iPod and iPhone, died Wednesday. He was 56. (AP Photo/Marcio Jose Sanchez, File) FILE - In this April 24, 2009 file photo, Dr. Ralph Steinman of Rockefeller University speaks during a news conference in Albany, N.Y. Rockefeller University in New York says Ralph Steinman, co-winner of this year's Nobel Prize in medicine, has died. The university says Steinman was diagnosed with pancreatic cancer four years ago and died on Sept. 30, three days before the announcement. (AP Photo/Mike Groll, File) FILE - In this Jan. 15, 2008, file photo, Apple CEO Steve Jobs holds up the new MacBook Air after giving the keynote address at the Apple MacWorld Conference in San Francisco. Apple on Wednesday, Oct. 5, 2011 said Jobs has died. He was 56. (AP Photo/Jeff Chiu, File) Fred Velez, of San Francisco, holds an Apple iPhone displaying an early picture of Steve Jobs, as he and others gather outside an Apple store in San Francisco on Wednesday, Oct. 5, 2011. Jobs, the Apple founder and former CEO who invented and masterfully marketed ever-sleeker gadgets that transformed everyday technology, from the personal computer to the iPod and iPhone, died Wednesday. He was 56. Apple announced his death without giving a specific cause. He died peacefully, according to a statement from family members who said they were present. (AP Photo/Darryl Bush)eval("var currentItemd57851005a80479aaeeb90a12c70b9ff = 1;");eval("var nextd57851005a80479aaeeb90a12c70b9ff = 0;");eval("var previousd57851005a80479aaeeb90a12c70b9ff = 0;"); Pancreatic cancer is notoriously lethal — there are almost as many deaths from it each year as there are new cases. The deaths this week of Apple founder Steve Jobs and Nobelist Ralph Steinman bring unusual attention to this less-well-known type of cancer.

Jobs lived more than seven years after being diagnosed with a neuroendocrine tumor — a less common, slower-growing and more treatable type of pancreatic cancer than the kind that killed Steinman a week ago and actor Patrick Swayze two years ago.

The Apple chief kept details of his illness behind a firewall and declared he was cured after cancer surgery in 2004. However, five years later, gaunt and having lost a lot of weight, Jobs had a liver transplant. Experts said it was likely because his cancer had returned or spread.

A liver transplant sometimes can cure the type of cancer that Jobs had. But if it comes back, "it's usually in one to two years," said Dr. Michael Pishvaian of Georgetown University's Lombardi Comprehensive Cancer Center.

In January, Jobs announced his third and final leave of absence. He resigned in August and died on Wednesday.

Part of what makes pancreatic cancer so deadly is that the pancreas is as vital as the heart. You can live with just part of a liver or a colon, or only one kidney or lung. But the pancreas is a fish-shaped organ that makes digestive enzymes and insulin and other hormones that enable the body to make energy from food.

In the United States, pancreatic cancer is the fourth leading cause of cancer deaths. About 44,030 people will be diagnosed with it and about 37,660 people will die of it this year in the U.S., the American Cancer Society estimates.

Over the past 15 to 25 years, rates of pancreatic cancer have dropped slightly, possibly because of a decline in smoking, the cancer society says. However, cases have been rising since around 2002 and rose about 1 percent per year over the period 1998 to 2007, said the cancer society's deputy chief medical officer, Dr. Len Lichtenfeld.

Possible symptoms are fatigue, back pain, abdominal pain, unexplained weight loss, loss of appetite, jaundice and nausea, according to the Lustgarten Foundation, a private group that finances research on the disease.

This cancer often is not found until it is advanced or has spread, and overall survival is dismal: 20 percent after one year and only 4 percent after five years.

However, with a neuroendocrine tumor like the one Jobs had, "people can live a longer time; median survival is five to eight years," said Dr. Alan Venook, a pancreatic cancer specialist at the University of California, San Francisco.

The lifetime risk of developing pancreatic cancer is about 1 in 71, according to the cancer society. Men and blacks account for more cases than women and whites, possibly because of differences in smoking rates. Smokers have two to three times more risk of developing the disease. Use of smokeless tobacco also raises the risk.

Obese people, those who don't exercise much and diabetics also have more risk for pancreatic cancer. Alcohol use might play a role: Most studies haven't tied it to pancreatic cancer, but heavy drinking can lead to diabetes and liver and pancreas problems that pose a cancer risk, the cancer society says.

The best hope for a patient is that the tumor is operable. That was the case in February 2009, when U.S. Supreme Court Justice Ruth Bader Ginsburg had a small, early-stage pancreatic tumor removed at New York's Memorial Sloan-Kettering Cancer Center.

On the horizon are immune system treatments — research that Steinman, the Nobel recipient from Rockefeller University in New York, was studying in the lab and trying on his own pancreatic cancer.

The immune system has a hard time recognizing and fighting cancer because the enemy is not an invading germ but our own cells gone rogue. Treatments called therapeutic cancer vaccines are ways to modify cells to help the immune system recognize the risk.

One such vaccine by NewLink Genetics, a small biotech firm in Ames, Iowa, is in late-stage testing now for pancreatic cancer. The company website says the larger study was initiated after a mid-stage test suggested improvement in survival.

Dr. Roderich Schwarz, chief of surgical oncology at the University of Texas Southwestern Medical Center in Dallas, has enrolled a few patients in some immune therapy studies, which have not paid off in the past.

"Vaccines are coming along," and last year's approval of one for advanced prostate cancer suggests researchers may be learning to overcome some of the drawbacks of the past, he said.

"It's quite possible that vaccines will claim their territory in the treatment of these challenging tumors," Schwarz said. "It's still in the development stage rather than the proven stage."

___

Online:

Cancer Institute: http://www.cancer.gov/cancertopics/types/pancreatic

Cancer Society: http://www.cancer.org/Cancer/PancreaticCancer/index

Survival rates: http://bit.ly/oAxKl5

Research and support: www.curePC.org and www.lustgarten.org

Vaccine study: http://www.linkp.com/products/hyperacute-pancreas.html

___

Marilynn Marchione can be followed at http://twitter.com/MMarchioneAP

Associated Press

Technology



News

New Efforts to Crack Down on Residential Programs for Troubled Teens

AppId is over the quota
AppId is over the quota

The first legislation aimed at regulating residential programs for troubled teens was introduced on Thursday in the House and the Senate. The bill would crack down on hundreds of programs housing thousands of teens, many of which use punishing "tough love" regimes found to include physical, sexual and emotional abuse.

The Stop Child Abuse in Residential Programs for Teens Act of 2011 was sponsored in the House by Rep. George Miller (D-Calif.) and in the Senate by Sen. Tom Harkin (D-Iowa). A previous version of the bill passed the House twice, but was never introduced in the Senate (at the time, the relevant Senate committee was focused on President Obama's health care legislation).

The legislation would prohibit sexual, physical and emotional abuse and would ban the use of deprivation — of food, sleep, clothing and shelter, for example — as punishment or for any other reason. The use of physical restraint would be permitted only for safety, and all programs would be required to provide residents with "reasonable" access to a telephone. It would require staff to be educated about what specifically counts as child abuse and how to report it, and mandate programs to disclose staff qualifications to parents.

Investigations by the Government Accountability Office (GAO) in 2007-08 found dozens of deaths related to abuse at such residential programs, along with thousands of further allegations, many confirmed, of abuse. GAO investigators posing as parents also discovered widespread use of fraudulent marketing practices.

MORE: Teens Made to Do Lap Dances in School in Supreme Court Case

"The culture of abuse and neglect at some of these programs is simply unacceptable, as is the inadequate staff training, regulation and state oversight. Every day we wait to take action is another day that the safety of teenagers is in jeopardy," said Miller. "I hope my Republican colleagues will join me in helping put an end to these horrific abuses that put the lives of too many children in danger."

Republicans, however, oppose additional federal regulations and believe these programs should be overseen by the states. "Ensuring the safety of the nation's youth is a priority for Americans on both sides of the political divide. We have learned a great deal about the abuse and neglect of troubled youth who live at residential treatment facilities," said Rep. John Kline (R-Minn.), chair of the House Education and the Workforce Committee, adding, "These at-risk youth deserve strong protections and we must ensure federal policies do not undermine the central responsibility of state and local leaders to ensure their safety and hold abusers accountable."

In 2009, I reported for TIME on allegations of sexual abuse at Mount Bachelor Academy, a residential program in Oregon owned by Aspen Education, the largest national operator of residential teen centers, which include wilderness programs and "emotional growth" boarding schools.

A state investigation that followed my article found that Mount Bachelor's treatment regime was "punitive, humiliating, degrading and traumatizing" and included "sexualized role play in front of staff and students." In March, the state also substantiated claims that neglect led to the death of a teen in another Aspen program, Sage Walk. That program had been featured on a short-lived reality show called "Brat Camp."

But while Oregon has some oversight of these programs, in many states, there is none at all. Nail salons and dog grooming outfits are, in fact, more strictly regulated than troubled teen programs, which routinely use corporal punishment and isolation in the guise of treatment.

MORE:
Increasingly, Internet Activism Helps Shutter Abusive 'Troubled Teen'

Boot Camps" href="http://healthland.time.com/2011/04/05/increasingly-internet-activism-helps-shutter-abusive-troubled-teen-boot-camps/">Increasingly, Internet Activism Helps Shutter Abusive 'Troubled Teen' Boot Camps

Cynthia Clark Harvey, whose daughter Erica died of heatstroke and dehydration after staff members of the Catherine Freer Wilderness program she attended insisted that she was faking her problems, testified during the first Congressional hearings held on the issue. "I support the legislation because it preserves true parental rights: the right to free and unmonitored communication with your child, the right to family-centered treatment and the right to know there are national standards that any program must adhere to," she said.

The new bill is supported by the American Psychological Association, the American Academy of Pediatrics, the Child Welfare League and the American Association of Children's Residential Centers. The National Association of Therapeutic Schools and Programs, an industry group, has said it supports the "intent" of the legislation but opposes federal regulation.

Maia Szalavitz is a health writer for TIME.com. Find her on Twitter at @maiasz. You can also continue the discussion on TIME Healthland's Facebook page and on Twitter at @TIMEHealthland.



News



Debt Financing

Severe hypoglycaemia cause found

AppId is over the quota
AppId is over the quota
7 October 2011 Last updated at 01:05 GMT Blood sugar test If blood sugar levels drop too far it can lead to unconsciousness The cause of a rare and severe form of hypoglycaemia - or very low levels of sugar in the blood - is genetic, say researchers.

The life-threatening condition means the body does not have enough energy to function.

Scientists at the University of Cambridge say mutations in the AKT2 gene are to blame.

Writing in the journal Science, they say there are already cancer drugs which target a similar process.

Hypoglycaemia can be caused by a disruption in the balance between the hormone insulin and sugar. Insulin lowers the level of sugar in the blood.

The condition is commonly associated with Type 1 diabetes, when the patients inject too much insulin, miss a meal or drink alcohol.

Rare However, one-in-100,000 babies are born with a genetic defect which means they develop hypoglycaemia even when there is no insulin in the blood. In theory they should have very high blood sugar levels.

These patients have to have a feeding tube inserted directly into the stomach to prevent fits while they are asleep.

One of the researchers, Dr Robert Semple, said: "Fear of low blood sugar has dominated the lives of these patients and their families."

Scientists analysed the genetic code of three children with the condition. All had a mutation in the AKT2 gene.

AKT2 acts as an interpreter for the hormone insulin. With the mutation, the interpreter acts as though insulin is always present, lowering blood sugar levels.

Lead researcher Prof Stephen O'Rahilly told the BBC that cancer drugs were available which targeted AKT1 and which also act against AKT2.

"There are actual pills that can be swallowed by humans, there could be a treatment in a year."



Debt Financing



Career Advisor

FDA approves Merck's new diabetes therapy combo

AppId is over the quota
AppId is over the quota
By Alina Selyukh

Fri Oct 7, 2011 1:23pm EDT

n">(Reuters) - U.S. health regulators approved a new combination therapy for type 2 diabetes from Merck & Co, the first to combine a diabetes drug with cholesterol-lowering medicine in one tablet.

Merck's new drug Juvisync combines the drugmaker's diabetes medicine Januvia, which helps lower high blood sugar levels, with simvastatin, a commonly prescribed statin that helps lower cholesterol alongside diet and exercise.

About 20 million Americans have type 2 diabetes, and many of them also have high cholesterol levels. The conditions can lead to increased risk of heart disease, stroke, kidney disease and blindness, especially if left untreated or poorly treated, the Food and Drug Association said.

For Merck, this is a chance to boost sales of Januvia, generically known as sitagliptin, whose sales rose 30 percent to $779 million in the second quarter.

The American Diabetes Association guidelines recommend statin therapy for anyone who has both diabetes and cardiovascular disease, regardless of cholesterol levels. They also recommend statins for anyone older than 40 with diabetes and with cardiovascular disease risk factors, such as high blood pressure.

Merck's experts have estimated that 6 million to 8 million of the type 2 diabetics who should be on a statin have not been receiving that therapy -- a gap that the company hopes to fill with the single-tablet Juvisync.

"Although clinical guidelines put people with diabetes at the same risk level as those with coronary heart disease, nearly 40 percent of eligible patients do not receive statin treatment," Dr. Barry Goldstein, Merck's vice president for diabetes and endocrinology, said in a statement. "We are proud to bring forward a treatment option that can help address this important health issue."

The FDA on Friday approved the combination in several dosage strengths.

The most common side effects of Juvisync include upper respiratory infection, stuffy or runny nose and sore throat, headache, muscle and stomach pain, constipation and nausea, regulators said.

Merck will now have to conduct a post-marketing clinical trial to compare how Januvia lowers glucose alone compared to its combination with simvastatin, the FDA said.

Merck's shares were up 1.5 percent at $31.88 in afternoon trading on the New York Stock Exchange.

Approved in 2006, Januvia was the first FDA-backed member of a new class of drugs called DPP-4 inhibitors that enhance the body's ability to lower elevated blood sugar. It has previously been coupled with another diabetes drug, metformin, and sold under the brand name Janumet. Merck's second-quarter sales of Janumet reached $321 million.

(Reporting by Alina Selyukh in Washington; additional reporting by Ransdell Pierson in New York and Anna Yukhananov in Washington; editing by John Wallace and Matthew Lewis)



New Automobile



Health Management

Weight loss plan 'lacks evidence'

AppId is over the quota
AppId is over the quota
6 October 2011 Last updated at 02:56 GMT By Helen Briggs Health editor, BBC News website Food Can you lose weight by changing your mindset? 'Nudging' people to lose weight by thinking about their lifestyle shows little evidence of success, an analysis of published data suggests.

It showed the step-by-step behavioural approach used in hospitals and clinics led to an average weight loss of 2kg (4.4lb) or less.

The report, by The Cochrane Library, looked at studies involving nearly 4,000 people around the world.

A nutritionist said changing one's mindset was not enough.

The method, known as the transtheoretical model stages of change, is used to encourage people to move towards more healthy forms of behaviour.

Continue reading the main story
Changing one's mindset is not enough. People need to eat less and exercise more to lose weight”

End Quote Spokesperson British Nutrition Foundation The five-step process encourages people to see the need to change and then give it a go.

It has been shown to be successful in helping people quit smoking, and has also been used in alcohol and drug addiction.

The analysis looked at five trials - in the UK, US, Netherlands, Canada, and Australia - involving 1,834 overweight or obese patients, and 2,076 people of normal weight.

The authors, led by Prof Azeem Majeed and Dr Nik Tuah of Imperial College London, found no convincing evidence of any sustained or significant weight loss.

Prof Majeed told the BBC: "Changing people's dietary patterns is very difficult - that's why we've got such a problem with obesity."

Dr Tuah added: "This review does not necessarily challenge the notion that diet and exercise are effective weight loss strategies, but instead raises questions about how to approach lifestyle changes for individuals who want to adopt them."

A spokesperson for the charity, the British Nutritional Foundation, said the report emphasised the need to take concerted action when trying to lose weight.

She said: "Changing one's mindset is not enough. People need to eat less and exercise more to lose weight."



Debt Financing



Career Advisor

Panel expected to say no prostate screenings for men

AppId is over the quota
AppId is over the quota
Study: Men don't need prostate examsNEW: Prostate Cancer Foundation spokesman calls recommendation a mistakeNEW: But author of report says he believes testing does more harm than goodU.S. Preventive Services Task Force to give prostate specific antigen testing a "D" ratingIt says tests bring "small or no reduction" in prostate cancer deaths

(CNN) -- The U.S. Preventive Services Task Force, the group that told women in their 40s that they don't need mammograms, will soon recommend that men not get screened for prostate cancer, according to a source privy to the task force deliberations.

The task force is set to recommend a "D" rating for prostate specific antigen, or PSA, testing. Such a rating means "there is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits," according to the group's website. The task force is set to propose this recommendation Tuesday, and then allow for a comment period before issuing a final recommendation.

According to a draft copy of a report released Friday, a review of studies shows screening with the PSA blood test results in "small or no reduction" in prostate cancer deaths.

The report adds that PSA testing is "associated with harms related to subsequent evaluation and treatments."

The PSA test, which is sometimes accompanied by a digital rectal exam, can help determine if a man has prostate cancer. The problem is that many of the cancers that get detected are so small and slow-growing, they'll never be harmful, and doctors have a difficult time discerning the quick, harmful cancers from the slow, harmless ones.

Empowered Patient: What's a dude to do?

If you test 100 men over age 50, 17 of them will have prostate cancer, and only three of those will have a fast-growing cancer and die of the disease, according to Dr. Kenneth Lin, senior author of the paper.

If the 14 men with the slow-growing cancers are treated, they could be rendered impotent or incontinent from the treatment; or worse, the treatment could kill them. About one in 500 men who has a radical prostatectomy will die because of complications of the surgery, according to Lin.

Some prostate cancer patients were disappointed with the task force's decision.

A spokesman for the Prostate Cancer Foundation called the proposed recommendation "a tremendous mistake."

"You're talking to someone whose life was saved by [the PSA test]," Dan Zenka said.

But Lin says he believes testing does more harm than good.

"Maybe you should get tested if you have this horrible family history where everyone gets prostate cancer before the age of 50. But for most men, testing is harmful," he said.

Until last year, Lin worked with the Preventive Services Task Force as a medical officer for the Agency for Healthcare Research and Quality. He says the task force voted in 2009 to give PSA screening a "D" rating, but it didn't announce it because of the uproar over the mammogram recommendation.

"I was so frustrated with the political interference, and this was the final straw," said Lin, who left the group in November and is now an assistant professor of family medicine at Georgetown University Medical Center.

CNN's Jennifer Bixler and Aaron Cooper contributed to this report.



Education Information



Technology

21 deaths now linked to listeria in cantaloupe

AppId is over the quota
AppId is over the quota
WASHINGTON (AP) — Federal health authorities say a nationwide outbreak of listeria in Colorado cantaloupes is now responsible for 21 deaths and the number may continue to grow.

The Centers for Disease Control and Prevention on Friday reported new deaths in Indiana and New York. The CDC also confirmed a death in Wyoming that state officials reported last week. CDC said 109 people have been sickened in the outbreak — including the 21 dead — in 23 states from California to the East Coast.

The agency previously reported five deaths in Colorado, five in New Mexico, two in Texas, two in Kansas and one each in Maryland, Missouri, Nebraska and Oklahoma. CDC said it is also aware of one miscarriage associated with the outbreak.

The death toll in the cantaloupe outbreak is now tied with a 1998 outbreak of listeria in hot dogs and possibly deli meats made by Bil Mar Foods, a subsidiary of Sara Lee Corp. That outbreak was also linked to 21 deaths. The deadliest outbreak in the United States before that is believed to have been listeria in Mexican-style soft cheese in 1985, which was linked to 52 deaths.

CDC officials have said the symptoms of listeria can take up to two months to show up and that they expect more illnesses through October.

Jensen Farms in Holly, Colo., recalled the tainted cantaloupes earlier this month after they were linked to listeria illnesses. They were shipped all over the country but should be off store shelves by now. The last cases of cantaloupes were shipped Sept. 10, and its shelf life is about two weeks.

The Food and Drug Administration has said state health officials found listeria in cantaloupes taken from Colorado grocery stores and from a victim's home that were grown at Jensen Farms. Matching strains of the disease were found on equipment and cantaloupe samples at Jensen Farms' packing facility in Granada, Colo.

The company has said they shipped the cantaloupe to around half of U.S. states, but added that they aren't sure where the cantaloupe went because it has been sold and resold. Thus, many companies may not even know if they bought or distributed the fruit. Fruit Fresh Up, Inc. of Depew, N.Y., issued a recall Thursday of 4,800 individual packages of cut cantaloupes, three weeks after the original recall and several days after the melons surpassed their freshness date.

FDA Commissioner Margaret Hamburg said this week that the agency is still investigating the cause of the outbreak. Officials have said they are looking at the farm's water supply and possible animal intrusions among other things to figure out the source of the problem. Listeria bacteria grow in moist, muddy conditions and are often carried by animals.

Officials from the CDC and the Food and Drug Administration say that any cantaloupes not from Jensen Farms are safe to eat. The recalled cantaloupes may be labeled "Colorado Grown," ''Distributed by Frontera Produce," ''Jensenfarms.com" or "Sweet Rocky Fords." Not all of the recalled cantaloupes are labeled with a sticker, the FDA said.

Government health officials said this is the first known outbreak of listeria in cantaloupe. Listeria is generally found in processed meats and unpasteurized milk and cheese, though there have been a growing number of outbreaks in produce.

Listeria is rare but more deadly than well-known pathogens like salmonella and E. coli. While most healthy adults can consume listeria with no ill effects, it can kill the elderly and those with compromised immune systems. It is also dangerous to pregnant women because it easily passes through to the fetus. The CDC said the median age of those sickened is 77, and most ill people are over 60 years old.

Symptoms include fever and muscle aches, often with other gastrointestinal symptoms.

The CDC has reported illnesses in Alabama, Arkansas, California, Colorado, Idaho, Illinois, Indiana, Iowa, Kansas, Maryland, Missouri, Montana, Nebraska, New Mexico, New York, North Dakota, Oklahoma, Oregon, South Dakota, Texas, Virginia, West Virginia, Wisconsin, and Wyoming. Colorado has the most illnesses, with 32 sickened. Texas has 16 reported illnesses, New Mexico has 13 and Oklahoma has 11.

___

Online:

CDC on cantaloupe outbreak: http://www.cdc.gov/listeria/index.html

FDA on cantaloupe recall: http://www.fda.gov/Food/FoodSafety/CORENetwork/ucm272372.htm

Center for Science and the Public Interest, "Super Safe Your Kitchen": http://www.cspinet.org/new/pdf/safekitchen.pdf

___

Find Mary Clare Jalonick on Twitter at http://twitter.com/MCJalonick

Associated Press

Technology



News

Women freezing eggs for future

AppId is over the quota
AppId is over the quota
"It's an insurance policy," Dr. Rachel Wellner says of freezing her eggs. An estimated 5,000 women nationwide are using egg-freezing technologyProcess costs thousands of dollars and it doesn't always workAmerican Society for Reproductive Medicine hasn't endorsed egg freezing

(CNN) -- When Dr. Rachel Wellner got a text from her brother Tuesday night that his wife was in labor, she was speaking at a fancy charity event for breast cancer research. As soon as her speech was over, she raced in her evening gown to Mount Sinai Hospital in Manhattan to watch her nephew, Lincoln Jacob Wellner, come into the world.

Holding the newborn baby in the delivery room, Wellner, 36, was overwhelmed with joy, but it was tinged with sadness as she wondered when -- or whether -- she would ever have a baby of her own. An accomplished breast surgeon, Wellner has no husband in sight.

Then she relaxed as she remembered what awaited her 50 blocks away: 13 eggs frozen in a bank at New York University Fertility Center.

If by the time Wellner gets married the eggs in her ovaries are too old to work, she can thaw out her frozen eggs, have them fertilized with her husband's sperm and implanted into her uterus, and hope that her younger eggs will succeed where her older eggs failed.

Freezing eggs for one's own future use has become a growing trend, with an estimated 5,000 women nationwide making use of the technology, according to Dr. Daniel Shapiro, medical director of the egg bank at Reproductive Biology Associates in Atlanta.

"I'm really hoping I find Mr. Right soon, but if I don't, having those eggs in the bank is a big weight off my shoulders," says Wellner, who banked her eggs in June.

"It empowers women," adds Dr. Jamie Grifo, program director of the New York University Fertility Center. "Patients get to be their own egg donors."

(Entertainment journalist Maria Menounos made news last week when she announced she's freezing her eggs, but it turns out she's actually doing something different -- read The Chart to find out what.)

"It's an insurance policy," says Wellner, director of breast services at the New York Eye and Ear Infirmary. "Maybe now I'll be one of those lucky girls who has babies later in life."

"I never thought I wouldn't have kids at this point."

Freezing your eggs may be an insurance policy, but it's an expensive one. It costs thousands of dollars (or in some cases, tens of thousands of dollars) and it doesn't always work.

Plenty of things can go wrong. Wellner's 13 eggs might not survive the freezing process. They might not create viable embryos when mixed with her future husband's sperm. And, even more likely, they might not attach to her uterus when doctors implant them.

That's why the American Society for Reproductive Medicine hasn't endorsed egg freezing, calling it experimental and unproven.

"Patients need to be advised there are some things we don't know," says Dr. Eric Widra, a spokesman for ASRM.

Pamela Madsen, founder of the American Fertility Association, says a woman has to decide whether it's worth it to take the financial risk.

"If not having a baby is not an option, then I'd go to Vegas and play my cards, knowing that it's Vegas," she says.

If you're considering preserving your eggs, here are five basic questions and answers:

1. How much will it cost?

Centers charge between $6,500 and $15,000 per cycle, according to Dr. Andrew Toledo, the CEO of Reproductive Biology Associates in Atlanta. RBA in Atlanta charges $7,600 per cycle, and NYU charges $12,000. Some women need more than one cycle to get enough viable eggs.

2. Will it work?

Shapiro at RBA estimates that a woman who freezes her eggs between the ages of 32 and 35 will have a 40 to 50% chance of achieving a successful pregnancy. If freezing between ages 35 and 38, the rate goes down to 35%. If freezing at 39 or 40, it's 20 to 25%, and if freezing eggs over age 40, the success rate will be less than 10%.

3. Can I find out in advance if it's worth the money to freeze my eggs?

A test for levels of anti-Mullerian hormone can help predict whether doctors will get enough eggs to make the procedure worthwhile.

"If the results are unfavorable, we say they're probably wasting their time and money," Shapiro says.

4. What's involved in freezing my eggs?

The procedure involves injecting yourself with medicines for 10 days, visiting the doctor¹s office five or six times. About two days later, doctors will harvest your eggs while you¹re under twilight sedation. Most women feel little pain aside from a bit of cramping and breast tenderness, and go back to work the next day.

5. How do I find the best place to freeze my eggs?

"Make them show you their data," Toledo advises. "How many patients have they treated? How many eggs did they get? What is the data on survivability when they're thawed?"

Wellner says even if her eggs don't work when she thaws them out, it was worth the financial risk.

"I spent all this money on my education. Twelve thousand dollars on my reproductive future is relatively inexpensive," she says.



Education Information



Technology

Steve Jobs Had LSD. We Have the iPhone

AppId is over the quota
AppId is over the quota

Days before Apple founder Steve Jobs died, the New York Times ran an op-ed proclaiming that "You Love Your iPhone. Literally." Our infatuation with our iPhones is not mere addiction, but genuine love, the piece asserted, because brain scans proved it. There's no doubt that Jobs' computers were the first of their kind to engender such widespread and ardent passion. So why did 45 neuroscientists write an angry letter to the Times disputing the science behind the contention?

The paradoxes of love have perhaps never been clearer than in our relationships with Apple products — the warm, fleshy desire we feel for such cold, hard, glassy objects. But Jobs knew how to inspire material lust. He knew that consumers want something that not only sparkles and awes, but also feels accessible, easy to use, an object with which we want to merge and to feel one and the same.

Not coincidentally, that's how people describe the experience of taking psychedelic drugs. It feels profoundly artificial yet deeply real, both high-tech and earthy-crunchy, human and mystically divine — in a word, transcendent. Jobs had this experience. He said that taking LSD was one of the two or three most important things he'd ever done. "He said there were things about him that people who had not tried psychedelics — even people who knew him well, including his wife — could never understand," John Markoff reported for the Times.

As attested by the nearly spiritual devotion so many consumers have to Jobs' creations, the former Apple chief (and indeed many other top technology pioneers) appeared to have found enduring inspiration in LSD. Research shows that the psychedelic experience is, in fact, long lasting: a new study published last week found that people who took magic mushrooms (psilocybin) had long-term personality changes, becoming more open, more curious, more intellectually engaged and more creative. These personality shifts persisted more than a year after taking the drugs.

MORE:
Change" href="http://healthland.time.com/2011/10/03/want-to-feel-younger-more-open-magic-mushrooms-trigger-lasting-personality-change/">'Magic Mushrooms' Trigger Lasting Personality Change

But back to the notion that we "love" our iPhones. As the angry neuroscientists pointed out in their letter to the Times, brain scanning technology can't identify love just by looking at what regions are active. It's not that simple. The op-ed writer said that subjects' insular cortexes — a brain region associated with feelings of love and compassion — lit up in response the sound of their phones, just as they would have responded to the presence of a romantic partner or family member. Problem is, the insula also lights up when people feel disgust and in about one-third of brain scanning experiments in general.

The op-ed tried to make the point that iPhone users' feelings about their devices surpassed addiction and entered the territory of love. But the truth is that addiction and love are probably indistinguishable, at least in the brain — both feelings fill you with desire and light up your pleasure regions. (If love isn't doing that for you, then you're doing it wrong.)

And brains don't have "addiction pathways," as is so often suggested. Rather, the key regions involved in addiction have evolved to ensure that humans find pleasure and reward in experiences like eating, sex and child-rearing — enough so that we survive and pass on our genes. Drugs merely mimic the body's own brain chemicals that underlie the experience of joy, desire and connection — and perhaps using an iPhone.

MORE: 'Magic Mushrooms' Can Improve Psychological Health Long Term

Here's what LSD and iPhones do have in common: they make us feel divinely connected to our environments and to other people, they lift mood and bring us joy, they enrich humanity. Is that love? Maybe. But at their worst, drugs and computers can also create distance and trigger addiction, which can destroy human connection and affection.

Maia Szalavitz is a health writer for TIME.com. Find her on Twitter at @maiasz. You can also continue the discussion on TIME Healthland's Facebook page and on Twitter at @TIMEHealthland.



News



Debt Financing

Pregnancy: Eating Well Cuts the Risk of Birth Defects

AppId is over the quota
AppId is over the quota

Need more of a reason to eat a healthy diet? Pregnant women who load up on fruits, veggies and whole grains have a reduced risk of having babies with neural tube defects, such as spina bifida or cleft lip, according to one of the first studies to look at the connection between diet and birth defects.

What that means for expectant mothers is that it's not enough just to take folic acid, which doctors recommend as a way to prevent up to 40% of neural tube defects (NTDs). As word has spread among pregnant women about the importance of a folic-acid supplementation, the number of babies born with NTDs has declined — but it hasn't dropped to zero. "We need to keep searching for answers," says Suzan Carmichael, lead author of the study published this week in the Archives of Pediatrics & Adolescent Medicine. 

Carmichael, an associate professor in the pediatrics department at Stanford University, decided to look at the importance of overall nutrition rather than focusing on a single nutrient such as folic acid.

MORE: Operating on Babies in the Womb: For Spina Bifida, It's the Better Option

Researchers studied 6,147 moms of babies without birth defects and 3,411 moms of babies born with NTDs and oral-facial clefts, all of whom were due between 1997 and 2005. They analyzed how closely each woman's diet hewed to two measures of diet quality: the Mediterranean diet and the U.S. Department of Agriculture food pyramid. Both diets emphasize healthy eating from various food groups, but the food pyramid stresses the importance of also including specific nutrients.

"One thing we know is nutrition is much more complex than a single nutrient," says Carmichael.

She found that women who ate the best-quality diets were up to 50% less likely to have a baby with anencephaly, a serious birth defect in which the brain doesn't fully form, than women who ate low-quality diets. They were up to 20% less likely to have a baby with spina bifida and up to 30% less likely to give birth to an infant with cleft lip or cleft palate. The highest-quality diets involved lots of fruits, vegetables and grains and fewer saturated fats and sweets.

MORE: Do We Need Vitamin-Supplemented Birth Control Pills?

The findings held true regardless of whether a woman took prenatal vitamins containing folic acid. "It's not to say that's not important, but we found the quality of diet matters," says Carmichael.

Bottom line: folic acid is important, but so is healthy eating.

Bonnie Rochman is a reporter at TIME. Find her on Twitter at @brochman. You can also continue the discussion on TIME's Facebook page and on Twitter at @TIME.



News



Debt Financing

NHS bosses urge honesty over cuts

AppId is over the quota
AppId is over the quota
7 October 2011 Last updated at 00:27 GMT By Adam Brimelow Health Correspondent, BBC News Hospital waiting room Managers have told the BBC that cuts are being presented as modernisation Health service managers have called on the government to be more honest about the financial challenges facing the NHS in England.

The NHS Confederation says a lack of candour over funding is damaging as the public may resist a service being cut.

This, say managers, can lead to potentially dangerous "salami slice" cuts across the board.

But the coalition government says health spending is growing and the NHS is becoming more efficient.

Compared with other departments, health did well in the coalition's spending review.

The government promised to increase funding in England in real terms, year on year, throughout this parliament.

But a lot of chief executives are pessimistic. They feel they are grappling with a spending squeeze, facing unpopular decisions involving cuts and closures without political cover.

Mike Farrar, chief executive of the NHS Confederation, says there is no public understanding of why changes are needed.

"It's very difficult for NHS managers and clinicians to make those necessary changes, and the alternative to getting public support for that is that they make unplanned cuts which are frankly in some cases rather dangerous to care that people need."

'Parallel universe'

A lot of this pressure comes from a plan called QIPP - Quality, Innovation, Productivity and Prevention.

This scheme, first announced under Labour, aims to save £20bn over four years through improved efficiency, with the money going back into front-line services.

But some trust chief executives - speaking anonymously - have told the BBC that the true agenda is about cuts.

One trust chief executive said ministers were not being straight with the public: "What people cannot tolerate is the lack of honesty about some of the tough choices that we're having to make.

"Wrapping it up in a language of modernisation and patient choice is simply unacceptable."

Another said: "Many chief executives - just about all that I speak to, believe that we're living in a parallel universe."

The bulk of the NHS budget still goes through primary care trusts.

Anita Charlesworth, former director of public spending at the Treasury who is now with the health research group the Nuffield Trust, says their real-terms funding increase has become a real-terms cut.

"The government has increased the money available to local health authorities to buy care by 3%.

"But when you take into account inflation and the fact of those health authorities being asked to hold back some money to prepare for contingencies and pay for one-off investments, the money that they've got available to spend with hospitals is 3% lower in real terms on average."

On top of this comes productivity savings - averaging 4-5% a year.

'No reinvestment'

The outlook for hospitals is even tougher.

In some places the strain is starting to show, with restrictions on access to services and a rise in the number of patients waiting more than 18 weeks for hospital treatment.

The chief executive of the Royal College of Nursing, Peter Carter - who ran a mental health trust for 12 years - says he hears this from managers all the time.

"They feel that they're being duplicitous for having to sell it to their staff, the public, their stakeholders by saying all of this money is coming back in. It is not coming back in. There is no evidence of any re-investment."

In a statement the Department of Health insisted that the service was becoming more efficient.

"Despite protecting the NHS budget, we know that the NHS will have to do more clinical work in the face of a flatter settlement - but that settlement is one of the best in Whitehall and we will keep our promise on increasing it in real terms."



Debt Financing



Career Advisor

Panel Advises Against Routine Prostate Screening

AppId is over the quota
AppId is over the quota
Visuals Unlimited, Inc. / Dr. Gladden Willis / Getty Images Visuals Unlimited, Inc. / Dr. Gladden Willis / Getty Images

No major medical group recommends routine PSA blood tests to check men for prostate cancer, and now a government panel is saying they do more harm than good and healthy men should no longer receive the tests as part of routine cancer screening.

The panel's guidelines had long advised men over 75 to forgo the tests and the new recommendation extends that do-not-screen advice to healthy men of all ages.

The recommendation by the U.S. Preventive Services Task Force, being made public on Friday, will not come as a surprise to cancer specialists.

Yet, most men over 50 have had at least one PSA blood test, the assumption being that finding cancer early is always a good thing.

Not so, said Dr. Virginia Moyer of the Baylor College of Medicine, who heads the task force.

"We have put a huge amount of time, effort and energy into PSA screening and that time, effort and energy, that passion, should be going into finding a better test instead of using a test that doesn't work," Moyer told The Associated Press late Thursday.

Too much PSA, or prostate-specific antigen, in the blood only sometimes signals prostate cancer is brewing. It also can mean a benign enlarged prostate or an infection. Worse, screening often detects small tumors that will prove too slow-growing to be deadly. And there's no sure way to tell in advance who needs aggressive therapy.

MORE: Saw Palmetto No Better Than Placebo for Prostate Symptoms

The task force analyzed all the previous research on this subject, including five major studies, to evaluate whether routine screening reduces deaths from prostate cancer. The conclusion: There's little if any mortality benefit.

But there is harm from routine screening: impotence, incontinence, infections, even death that can come from the biopsies, surgery and radiation, Moyer said.

One study estimated 2 of every 5 men whose prostate cancer was caught through a PSA test had tumors too slow-growing to ever be a threat.

Yet Moyer said 30 percent of men who are treated for PSA-discovered prostate cancer suffer significant side effects, sometimes death, from the resulting treatment.

About a third of men ages 40 to 60 have brewing prostate cancer but "the huge majority of them will never know it in their lifetime if they are not screened," she added.

MORE: Screening for Ovarian Cancer Doesn't Increase Women's Survival

The task force previously had considered the evidence for or against PSA screening inconclusive. The new recommendation says not to routinely screen. That recommendation is a draft that is open for public comment beginning next week.

"We have been long concerned, and it has been apparent for some years, that some supporters of prostate cancer screening have overstated, exaggerated and in some cases misled men about the evidence supporting its effectiveness," said Dr. Otis Brawley of the American Cancer Society in a statement. "We need balanced, truthful information to be made widely available to physicians and patients when making important health decisions."

The society had not seen the new recommendation yet, but has long advised men to consider the pros and cons of PSA screening before deciding on their own.

Moyer said the recommendation only means that doctors shouldn't bring up the option for healthy men. If a man asks for a PSA test and wants it after being informed of the evidence, he should receive it, she said. Likewise, it's appropriate to use PSA tests to examine a man with possible prostate symptoms.

—By LAURAN NEERGAARD



News



Debt Financing

Why pancreatic cancer is so deadly

AppId is over the quota
AppId is over the quota
Steve Jobs had a pancreatic neuroendocrine tumor. Apple Inc. announced his death Wednesday.Steve Jobs had a pancreatic neuroendocrine tumor. Apple Inc. announced his death Wednesday.About 95 percent of people with pancreatic cancer die from it, experts sayAs people age, the risk of developing pancreatic cancer goes upThe pancreas is an oblong organ that lies deep in the abdomenThere are two types of pancreatic cancer: exocrine tumors and endocrine tumors

(CNN) -- As the technology world mourns computing visionary and Apple, Inc. co-founder Steve Jobs, it's worth taking a closer look at the disease he publicly battled.

Jobs had a rare form of pancreatic cancer called a neuroendocrine tumor. Patrick Swayze, Joan Crawford, Margaret Mead and Luciano Pavarotti all died from a more common form of pancreatic cancer, called adenocarcinoma. Supreme Court Justice Ruth Bader Ginsburg underwent surgery for pancreatic cancer in February 2009 and, 18 days later, returned to the bench.

"Right now, pancreatic cancer is getting publicity, but it's a neglected disease," said Dr. Michaela Banck, medical oncologist at the Mayo Clinic, who treats patients with neuroendocrine tumors. "It doesn't draw the same attention as colon cancer and breast cancer. Activist groups raise small amounts of money, since it's a rare disease. It's a complicated disease. We don't have enough money to make progress as fast as we'd like to."

Who gets pancreatic cancer

Pancreatic cancer is the fourth-leading cause of death from cancer in the United States, after lung, colon and breast cancer. The lifetime risk of developing it is about 1 in 71. This year, about 44,030 people will be diagnosed with pancreatic cancer, and the disease will kill about 37,660 people, according to the American Cancer Society.

About 95 percent of people with pancreatic cancer die from it, experts say. It's so lethal because during the early stages, when the tumor would be most treatable, there are usually no symptoms. It tends to be discovered at advanced stages when abdominal pain or jaundice may result. Presently, there are no general screening tools.

Rates of pancreatic cancer have dropped slightly among men and women over the past 15 to 25 years.

As people age, the risk of developing pancreatic cancer goes up. Most patients are older than 45, and nearly 90% are older than 55. The average age at diagnosis is 72.

Men have a slightly higher likelihood of developing pancreatic cancer than women, which may partly result from increased tobacco use in men. In the past, when men more commonly smoked than women, the gender gap was wider.

There is also a noted association with race: African-Americans are more likely to develop pancreatic cancer than whites. Doctors don't know why, but speculate that higher rates of men smoking and having diabetes, and women being overweight, may contribute to that association.

What are the types of pancreatic cancer?

The pancreas is an oblong organ that lies deep in the abdomen, and is an integral part of both the digestive and endocrine system. It secretes hormones to regulate the body and also digestive enzymes to break down food.

There are two types of pancreatic cancer: exocrine tumors and endocrine tumors.

Exocrine tumors are the majority of pancreatic cancers, and the most common form is called adenocarcinoma, which begin in gland cells, usually in the ducts of the pancreas. Swayze died from this kind of pancreatic cancer. These tumors tend to be more aggressive than neuroendocrine tumors, the kind that Jobs had, but if caught early enough they can be treated effectively with surgery.

Pancreatic neuroendocrine tumors constitute only 1% of all pancreatic cancers. They can be benign or malignant, but the distinction is often unclear and sometimes apparent only when the cancer has spread beyond the pancreas.

The five-year survival rate for neuroendocrine tumors can range from 50% to 80%, compared with less than 5% for adenocarcinoma.

More advanced tumors have a higher risk of recurrence, and can spread to the liver, said Dr. Steven Libutti, pancreatic cancer expert and director of the Montefiore-Einstein Center for Cancer Care in the Bronx.

Treatment options

Pancreatic cancer is usually controllable only through removal by surgery, and only if found before it has spread, according to the National Cancer Institute. Palliative care can help a patient's quality of life if the disease has spread.

Two new drugs approved this year may help patients with pancreatic neuroendocrine tumors. They are believed to suppress the blood supply and metabolism of the tumor cells. That's good progress since, a year ago, the standard of care was chemotherapy, Banck said.

Everolimus, marketed by Novartis as Afinitor, received U.S. Food and Drug Administration approval to treat pancreatic neuroendocrine tumors and prevents transplant rejection. Potential side effects are serious, however: lung or breathing problems, infections and renal failure, which may lead to death.

Sunitinib malate, marketed by Pfizer as Sutent, is prescribed for the treatment of pancreatic neuroendocrine tumors, as well as, kidney cancer and GIST, a rare cancer of the bowel, esophagus or stomach. As with everolimus, there are risks to consider: it can cause liver problems and death.

Given that Jobs underwent surgery to remove his tumor in 2004 and died in 2011, his seven-year survival after treatment is consistent with the average survival for these kinds of tumors, Libutti said.

If pancreatic cancers are detected early, that may increase the odds of survival, but it also depends on how aggressive the particular tumors are in a patient. If surgery leaves behind microscopic aggressive tumor cells, they can cause a recurrence of cancer.

Jobs also underwent a liver transplant in Tennessee in 2009, which is "cutting edge stuff" for when neuroendocrine tumors spread, said Dr. Maged Rizk, director of the Chronic Abdominal Pain Center at the Cleveland Clinic who specializes in gastroenterology and hepatology.

Did Steve Jobs' money buy him a faster liver transplant?

But because it's so rare, there isn't a lot of evidence to support the transplant as a cure; the procedure could extend life, but immunosuppression drugs may allow any remaining cancer to grow faster, doctors say. And a European study found that the majority of patients who underwent liver transplant for this type of tumor had recurrence of the disease.

But many pancreatic cancers are detected in later stages because when the tumor is small, it often does not produce symptoms. As they grow, adenocarcinomas can obstruct the ducts from the liver and cause severe back pain. Neuroendocrine tumors sometimes produce insulin, so a patient's first symptoms could be low glucose levels. But most tumors do not produce hormones, Libutti said.

There are two rare genetic syndromes -- multiple endocrine neoplasia type 1 (MEN1) and Von Hippel-Lindau syndrome (VHL) -- that increase the risk of pancreatic neuroendocrine tumors. Other than that, though, it's unclear whether having a family member with pancreatic cancer increases an individual's risk.

Pancreatic cancer struck former President Jimmy Carter's family hard. He lost his father and all of his siblings, brother Billy and sisters Ruth Carter Stapleton and Gloria Carter Spann.

The future of treatment

Researchers are working on better understanding the way in which pancreatic tumors grow and spread, Libutti said.

"There are a number of agents that are being looked at in clinical trials that focus on pathways that may allow pancreatic cancer to evade normal processes," Libutti said.

One is an antibody that blocks a particular protein called PD-1 on the surface of pancreatic cancer, meaning chemotherapies would be more effective because there would be an enhanced immune response against the tumor. That work is being done by the National Cancer Institute.

Libutti's lab is working on targeted nanoparticle therapies for metastatic neuroendocrine tumors. The idea is that tiny particles are coated with material that hones in on tumor cells and delivers drugs to kill them without harming healthy tissue, reducing the toxicity to the body in general. This research is still in animal models.

"We're hopeful that in the not-too-distant future, we'll be ready to move into clinical trials," he said.

Another line of research is focused on finding biomarkers of pancreatic cancer so that a simple blood or urine test could be developed. Unlike screenings for other conditions such as colon, breast and prostate cancers, there is no routine way to see whether a patient has a tumor in the pancreas.

The future of medicine to help people with pancreatic cancer will involve genetics, said Banck. This would involve matching a person's particular type of tumor using genomic information with treatment.

"What's going to make real difference in the future is the revolution of the genomic era," she said.

CNN's Madison Park and Jacque Wilson contributed to this report.



Education Information



Technology

Risky pregnancy drug raised daughters' cancer odds

AppId is over the quota
AppId is over the quota
This Tuesday, Oct. 4, 2011 photo shows Debbie Wingard in her office at the University of California-San Diego where she is a professor. Wingard has had breast cancer twice and has been unable to conceive which she believes is due to her mother's use of the drug DES during pregnancy. The drug that millions of pregnant women took decades ago to prevent miscarriage and complications has put their daughters at higher risk for breast cancer and other health problems that are showing up now, a new federal study finds. (AP Photo/Lenny Ignelzi) This Tuesday, Oct. 4, 2011 photo shows Debbie Wingard in her office at the University of California-San Diego where she is a professor. Wingard has had breast cancer twice and has been unable to conceive which she believes is due to her mother's use of the drug DES during pregnancy. The drug that millions of pregnant women took decades ago to prevent miscarriage and complications has put their daughters at higher risk for breast cancer and other health problems that are showing up now, a new federal study finds. (AP Photo/Lenny Ignelzi) This Wednesday, Oct. 5, 2011 photo shows Jackie White in Branchville, N.J. White, a breast cancer survivor and a DES daughter who lives in Centerburg, Ohio, north of Columbus, said she had a misshaped uterus and reproductive problems, and found a lump last year that turned out to be breast cancer. Tests showed 20 tumors in one breast, two pre-cancers in the other and spread to her lymph nodes. The drug that millions of pregnant women took decades ago to prevent miscarriage and complications has put their daughters at higher risk for breast cancer and other health problems that are showing up now, a new federal study finds. (AP Photo/Julio Cortez) This Tuesday, Oct. 4, 2011 photo shows Debbie Wingard outside the Stein Clinical Research building at the University of California-San Diego where she is a professor. Wingard has had breast cancer twice and has been unable to conceive which she believes is due to her mother's use of the drug DES during pregnancy. The drug that millions of pregnant women took decades ago to prevent miscarriage and complications has put their daughters at higher risk for breast cancer and other health problems that are showing up now, a new federal study finds. (AP Photo/Lenny Ignelzi) This Wednesday, Oct. 5, 2011 photo shows Jackie White in Branchville, N.J. White, a breast cancer survivor and a DES daughter who lives in Centerburg, Ohio, north of Columbus, said she had a misshaped uterus and reproductive problems, and found a lump last year that turned out to be breast cancer. Tests showed 20 tumors in one breast, two pre-cancers in the other and spread to her lymph nodes. The drug that millions of pregnant women took decades ago to prevent miscarriage and complications has put their daughters at higher risk for breast cancer and other health problems that are showing up now, a new federal study finds. (AP Photo/Julio Cortez)eval("var currentItemd57851005a80479aaeeb90a12c70b9ff = 1;");eval("var nextd57851005a80479aaeeb90a12c70b9ff = 0;");eval("var previousd57851005a80479aaeeb90a12c70b9ff = 0;"); A drug that millions of pregnant women took decades ago to prevent miscarriage and complications has put their daughters at higher risk for breast cancer and other health problems that are showing up now, a new federal study finds.

Many of these daughters, now over 40, may not even know of their risk if their mothers never realized or told them they had used the drug, a synthetic estrogen called DES.

The new study suggests that infertility is twice as common and that breast cancer risk is nearly doubled in these daughters.

Debbie Wingard is one of them. The 59-year-old San Diego woman adopted two boys after being unable to conceive and has had breast cancer twice — when she was 39 and 49.

"There's no knowing what's going to happen as we age. There's always the fear there's going to be another cancer or another outcome," she said. "I don't think I'll ever get to the point where I feel it's behind me."

The sons of DES users also face health risks — testicular problems and cysts — but these are less well studied and don't seem to be as common. Even less is known about the third generation — "DES grandchildren." Some research suggests these girls start menstruating late and have irregular periods, possible signs of fertility issues down the road.

In the United States alone, more than 2 million women and 2 million men are thought to have been exposed to DES while in the womb and may now want to talk with their doctors about when they should be screened for health problems.

"We don't want to cause a panic of everyone rushing out thinking they're going to get cervical or breast cancer. They just need to have that conversation with their physician," said Dr. Sharmila Makhija, women's health chief at the University of Louisville.

The average woman has about a 1 in 50 chance of developing breast cancer by age 55; for DES daughters it's 1 in 25, the study found. Risks for other health problems vary.

DES, or diethylstilbestrol, was widely used in the United States, Europe and elsewhere from the 1940s through the 1960s to prevent miscarriage, premature birth, bleeding and other problems. Many companies made and sold it as pills, creams and other forms.

Studies later showed it didn't work. The government told doctors to stop using it in pregnancy in 1971, after DES daughters in their late teens and 20s were found to be at higher risk of a rare form of vaginal cancer. Further research has tied DES to infertility and various pregnancy problems.

"They've been identified one at a time. Nobody's been able to get the whole picture," said Dr. Robert Hoover, a researcher at the National Cancer Institute. The new study, which he led, "takes the woman and looks at everything that can happen as a result of this drug," and adds evidence for some previously suspected risks like breast cancer, he said.

Results are in Thursday's New England Journal of Medicine.

The study started in 1992 and involved about 4,600 DES daughters and a comparison group of 1,900 similar women whose mothers had not used DES. Their health was tracked over time through surveys and medical records. Their average age at the last followup was 48.

In the study, researchers found these rates of health problems in DES daughters compared to non-exposed women:

—Breast cancer, 3.9 percent versus 2.2 percent.

—Cervical pre-cancer, 6.9 percent versus 3.4 percent.

—Infertility, 33.3 percent versus 15.5 percent.

—Early menopause, 5.1 percent versus 1.7 percent

These complications were seen among women who were able to become pregnant:

—Preterm delivery, 53.3 percent versus 17.8 percent.

—Miscarriage, 50.3 percent versus 38.6 percent.

—Tubal pregnancy, 14.6 percent versus 2.9 percent.

—Stillbirth, 8.9 percent versus 2.6 percent.

—Preeclampsia (high blood pressure during pregnancy), 26.4 percent versus 13.7 percent.

The claim of added breast cancer risk is being tested by 53 women in a lawsuit against DES makers under way now in Boston. One of them is Jackie White, 48, who lives in Centerburg, Ohio, north of Columbus. She said she had a misshaped uterus and reproductive problems, and found a lump last year that turned out to be breast cancer. Tests showed 20 tumors in one breast, two pre-cancers in the other and spread to her lymph nodes.

"I ate a low-fat diet. I exercise faithfully so I was not overweight. I had none of the normal risk factors," she said.

When and how often to screen women for breast cancer is the subject of much debate. A government task force recommends that women at average risk of breast cancer get mammograms every other year starting at age 50, and talk to their doctors about screening before then. Many medical groups urge starting at age 40.

DES exposure needs to be considered with the whole picture of a woman's risk, said Dr. G. Wright Bates, director of reproductive medicine at the University of Alabama at Birmingham.

"In some cases, frequent Pap smears and early mammography or breast MRI may be warranted for women with DES exposure," he said.

Others are focused on possible risks to the next generation.

Sally Keely, who was part of the federal study, and her husband are both offspring of women who took DES during pregnancy. Keely, 49, of Kalama, Wash., had miscarriages and a tubal pregnancy and required fertility treatments to have a daughter, now 9.

"I would like to push for more funding on the third generation exposed so I would know best how to advise my daughter," she said.

Fran Howell, executive director of DES Action USA, an advocacy group based in Jupiter, Fla., adopted a daughter, now 20, after being unable to conceive.

"So many of the DES daughters worry about problems with their children," she said. "The DES ends with me."

___

Online:

Cancer Institute: http://www.cancer.gov/cancertopics/factsheet/Risk/DES.

CDC: http://www.cdc.gov/des/consumers/about/concerns_daughters.html

Advocacy group: www.desaction.org

___

Marilynn Marchione can be followed at http://twitter.com/MMarchioneAP

Associated Press

Technology



News

Scientists hail gain in human embryonic stem cell research

AppId is over the quota
AppId is over the quota
The achievement is an "important step" in stem cell research, scientists say They used a technique similar to the one used to clone Dolly the sheepThe motivation for the research was to eventually cure diseases such as Parkinson's, diabetes

(CNN) -- For the first time, researchers have succeeded in creating human embryonic stem cells by injecting DNA from a skin cell into an unfertilized egg, according to a study published Wednesday.

To achieve what is being called an "important step" in stem cell research, scientists in New York used a cloning technique similar to the one used to clone Dolly the sheep.

"This work now demonstrates for the first time that the human egg has the ability to turn a specialized cell into a stem cell," said Dieter Egli, who along with fellow study author Scott Noggle led the research team at the New York Stem Cell Foundation.

"The goal of this research was to create patient-specific embryonic stem cells with the patients' DNA for the eventual use in cell replacement therapy," Egli told CNN.

He said the motivation for the research was to eventually cure diseases such as Parkinson's, diabetes and many other illnesses.

In 2005, researchers in South Korea claimed to have created the first human embryonic stem cells by cloning an embryo. A year later, it was revealed that the data had been faked.

This new study, published in the journal Nature, shows researchers have finally succeeded in creating human embryonic stem cells. They weren't perfect though because they have too many chromosomes -- 69 instead of the usual 46 -- making the cells suitable for research purposes only, not actual treatments.

In the past, efforts to create human stem cells using cloning meant taking an unfertilized egg, removing egg's nucleus with its 23 chromosomes and replacing it with the nucleus of a skin cell (which has 46 chromosomes) and placing the egg in a chemical bath to make it divide as if it had been fertilized by sperm.

Researchers started out with 270 donated oocytes or unfertilized eggs, provided by sixteen egg donors, Noggle said.

Egli said through a process of elimination, he and his colleagues determined that it was the removal of the egg's genome, not the introduction of new DNA or chemically initiating cell division, which was preventing the egg to develop far enough along so stem cells can be extracted. Noggle says 63 eggs were needed to develop two cell lines, of which one was viable.

"It's the machinery within the egg that allows the egg to progress normally in development," said Ted Golos, who is a professor of Comparative Biosciences at the school of Veterinary Medicine at the University of Wisconsin-Madison.

Golos, who is not involved in this new research, says this new study isn't a giant leap forward but it's an interesting one. Now the challenge is to figure out how to remove the egg's chromosomes, without removing the machinery or spindle, which helps the egg divide. Egli said he and his colleagues are working on just that.

Researchers have been using adult stem cells like bone marrow for treatments for decades. But adult stem cells have been programmed for one part of the body and are not easily converted to correcting problems in other parts of the body.

Then the first major advance in human embryonic stem cell research came In 1998, when Jamie Thomson at the University of Wisconsin-Madison, extracted the first stem cells from an existing human embryo.

In 2007, researchers in Japan and California reported the creation of stem cells by bypassing eggs altogether and reprogramming skin cells directly into dividing like fertilized eggs with the addition of four viruses.

These cells are called induced pluripotent stem cells or iPS cells. Since then, researchers have found these cells have some limitations as well. While some opponents of embryonic research believe advances in the "less controversial" adult stem cell and iPS cells eliminate the need for embryonic stem cell research, most experts in the field believe all three research paths need to be explored to eventually find the right treatment for the right disease.

Dr. Alan Trounson, who heads the California Institute for Regenerative Medicine, which funds embryonic and adult stem cell research, says if researchers are able to take the next step and figure out how to make embryonic stem cells without the excess chromosomes, then they can begin to compare them to iPS cells and determine how different or similar they really are.

Egli agrees.

"We need to better understand the biology of the human egg for reprogramming without the egg genome," he said.



Education Information



Technology